ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
2 announcements with these filters
Rubicon Research disclosed a US FDA inspection at its Pithampur facility, yielding 2 procedural observations. The company is confident in resolving them, with no impact on data integrity or operations.
Rubicon Research Limited announced the successful conclusion of an unannounced USFDA inspection at its R&D facility in Concord, Ontario, Canada. The inspection, conducted from April 20 to April 24, 2026, concluded without any Form-483 observations being issued. This outcome confirms the company's adherence to high quality and compliance standards.